Inactive Instrument

OHR Pharmaceutical Inc Stock price Nasdaq

Equities

US67778H3093

Biotechnology & Medical Research

Sales 2023 * - Sales 2024 * - Capitalization 1.69M
Net income 2023 * -12M Net income 2024 * - EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-0.06 x
P/E ratio 2024 *
-
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 86.56%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on OHR Pharmaceutical Inc

Managers TitleAgeSince
Chief Executive Officer 54 22-01-09
Corporate Officer/Principal - -
Corporate Officer/Principal - 21-10-31
Members of the board TitleAgeSince
Chairman 56 19-07-11
Director/Board Member 63 19-07-11
Director/Board Member 79 19-07-11
More insiders
NeuBase Therapeutics, Inc. is a preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company’s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntington’s disease (HD), and oncology and in gene editing applications. It also focused on identifying and evaluating multiple indications for potential development.
More about the company
  1. Stock
  2. Equities
  3. Stock NeuBase Therapeutics, Inc.
  4. Stock OHR Pharmaceutical Inc - Nasdaq